Drug Cloud
Anybody who’s used an inhaler to treat asthma or allergies is familiar with the medicinal aftertaste. That taste is more than an annoyance-it’s a sign that a portion of the drug is going to waste in the back of the throat rather than in the lungs where it’s needed. Battelle Pulmonary Therapeutics-a company spun off in April from Battelle Memorial Institute in Columbus, Ohio-is aiming to deliver inhalable drugs more efficiently with new “electrohydrodynamic,” or EHD, aerosol technology.
EHD devices use voltage, rather than pressure, to create a “soft cloud” of aerosolized drug. The patient inhales the cloud, rather than having aerosol shot into the mouth at a velocity that propels drug particles against the throat. The new company believes EHD technology will be valuable against a number of respiratory diseases and infections, including bronchitis and pneumonia. As TR went to press, the startup had signed two licensing agreements-one to commercialize an anti-viral device-and was working on several other deals.
Keep Reading
Most Popular
Geoffrey Hinton tells us why he’s now scared of the tech he helped build
“I have suddenly switched my views on whether these things are going to be more intelligent than us.”
Meet the people who use Notion to plan their whole lives
The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.
Learning to code isn’t enough
Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.
Deep learning pioneer Geoffrey Hinton has quit Google
Hinton will be speaking at EmTech Digital on Wednesday.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.